![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00508365 |
This is a multi-center, double-blind, randomized, placebo-controlled, 2-session crossover study to evaluate the incidence of orthostatic hypotension in elderly hypertensive subjects following co-administration of carvedilol CR and lisinopril.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: carvedilol CR + lisinopril |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Safety Study |
Official Title: | A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of Carvedilol CR and Lisinopril |
Enrollment: | 40 |
Study Start Date: | September 2007 |
Study Completion Date: | June 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Subject is receiving ongoing treatment or is anticipated to receive treatment with any of the following medications during the study:
Subject has any of the following conditions:
Any of the following abnormalities on 12-lead ECG during screening:
United States, Alabama | |
GSK Investigational Site | |
Anniston, Alabama, United States, 36207 | |
United States, Arizona | |
GSK Investigational Site | |
Glendale, Arizona, United States, 85308 | |
United States, California | |
GSK Investigational Site | |
Anaheim, California, United States, 92801 | |
GSK Investigational Site | |
Long Beach, California, United States, 90806 | |
United States, Florida | |
GSK Investigational Site | |
Sarasota, Florida, United States, 34239 | |
GSK Investigational Site | |
West Palm Beach, Florida, United States, 33409 | |
GSK Investigational Site | |
Coral Gables, Florida, United States, 33134 | |
GSK Investigational Site | |
Miami, Florida, United States, 33169 | |
United States, Idaho | |
GSK Investigational Site | |
Boise, Idaho, United States, 83704 | |
United States, Indiana | |
GSK Investigational Site | |
Indianapolis, Indiana, United States, 46260 | |
United States, Nevada | |
GSK Investigational Site | |
Las Vegas, Nevada, United States, 89119 | |
United States, New Jersey | |
GSK Investigational Site | |
Hackensack, New Jersey, United States, 07601 | |
United States, North Dakota | |
GSK Investigational Site | |
Fargo, North Dakota, United States, 58103 | |
United States, Ohio | |
GSK Investigational Site | |
Cleveland, Ohio, United States, 44122 | |
United States, Oklahoma | |
GSK Investigational Site | |
Oklahoma City, Oklahoma, United States, 73132 | |
United States, Oregon | |
GSK Investigational Site | |
Portland, Oregon, United States, 97239 | |
United States, Texas | |
GSK Investigational Site | |
Houston, Texas, United States, 77081 | |
GSK Investigational Site | |
Austin, Texas, United States, 78704 | |
GSK Investigational Site | |
San Antonio, Texas, United States, 78229 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | CFD109701 |
Study First Received: | July 26, 2007 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00508365 |
Health Authority: | United States: Food and Drug Administration |
hypertension carvedilol lisinopril |
Hypotension Postural hypotension Hypotension, Orthostatic Lisinopril |
Vascular Diseases Carvedilol Hypertension |
Neurotransmitter Agents Vasodilator Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Adrenergic alpha-Antagonists |
Antihypertensive Agents Protective Agents Pharmacologic Actions Protease Inhibitors Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists |